Dr. Coleman on Benefit of Rucaparib in Ovarian Cancer
March 28th 2019Robert Coleman, MD, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the benefit of rucaparib in the treatment of patients with ovarian cancer.
Encorafenib/Binimetinib-based Triplet Added to NCCN Guidelines for BRAF+ CRC
March 18th 2019The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer to include the regimen of encorafenib and binimetinib plus EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with BRAF V600E–mutant metastatic colorectal cancer, after failure of 1 or 2 lines of therapy for metastatic disease.
Dr. Wierda on Novel Therapies in Relapsed/Refractory CLL
March 13th 2019William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel therapies in patients with relapsed/refractory chronic lymphocytic leukemia.
Dr. Meric-Bernstam on CB-839 Plus Cabozantinib in RCC
March 8th 2019Funda Meric-Bernstam, MD, chair, Department of Investigational Cancer Therapeutics, medical director, Institute for Personalized Cancer Therapy, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses the combination of CB-839 plus cabozantinib in patients with renal cell carcinoma.
Dr. Wierda on Treatment of Relapsed/Refractory CLL
March 7th 2019William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.
Dr. Katz on Preoperative Chemoradiation in Localized Pancreatic Cancer
March 5th 2019Matthew H.G. Katz, MD, FACS, associate professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses preoperative chemoradiation for the treatment of patients with localized pancreatic cancer.
Dr. Cortes on Exploring the Use of Quizartinib in AML
March 5th 2019Jorge E. Cortes, MD, deputy chair of the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the data from the QuANTUM-R trial presented at the 2018 ASH Annual Meeting in relapsed/refractory acute myeloid leukemia (AML).
Molecular Testing Needed to Inform CRC Treatment Decisions
Michael Overman, MD, highlights data from pivotal trials presented at the 2019 Gastrointestinal Cancers Symposium and discusses where research efforts should be focused to improve the treatment of patients with colorectal cancer.
Dr. Verstovsek on Toxicity Profile of Ruxolitinib in MPNs
February 22nd 2019Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the toxicity profile of ruxolitinib in the treatment of patients with myeloproliferative neoplasms.
Dr. Subudhi Discusses Rationale for CheckMate-650 Study in Prostate Cancer
February 21st 2019Sumit K. Subudhi, MD, PhD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rationale for the CheckMate-650 study in the treatment of patients with metastatic castration-resistant prostate cancer.
Dr. Verstovsek on Benefit of Ruxolitinib in Polycythemia Vera
January 31st 2019Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the benefit of ruxolitinib in polycythemia vera.